Filtered By:
Infectious Disease: SARS
Management: Hospitals
This page shows you your search results in order of date.
Order by Relevance | Date
Total 227 results found since Jan 2013.
Asthma in elderly and COVID-19: results of 90-day post-hospital follow-up
Once the first wave of SARS-CoV-2 novel coronavirus disease subsided, the attempt was made to investigate both short- and long-term potential consequences, especially in high-risk patient cohorts including those after prolonged hospitalization and intensive therapy1. Symptoms persisting 3 - 6 months after acute COVID-19 (post-COVID syndrome) have been described 2,3,4,5. Currently, there is a lack of information on post-COVID consequences in elderly patients with asthma. Asthma in elderly is known to have specific features, such as high comorbidity, use of multiple pharmacological agents, individual response to treatment, d...
Source: Annals of Allergy, Asthma and Immunology - August 7, 2023 Category: Allergy & Immunology Authors: Sergey N. Avdeev, Viliya V. Gaynitdinova, Anna A. Pozdnakova, Svetlana Yu Chikina, Karina A. Kosobokova Tags: Letters Source Type: research
Study provides deeper insight into long COVID
This study is an important step toward defining long COVID beyond any one individual symptom, " said study author Dr. Leora Horwitz, director of the Center for Healthcare Innovation and Delivery Science and co-principal investigator for the RECOVER Clinical Science Core at NYU Langone Health. " This research definition — which may evolve over time — will serve as a foundation for scientific discovery and treatment design. "The researchers say studying the underlying biological mechanisms of long COVID is central to advancing informed interventions and identifying effective treatment strategies.
In addition to establish...
Source: The University of Arizona: Health - May 30, 2023 Category: Universities & Medical Training Authors: mittank Source Type: research
Companies won ’t share COVID-19 shots, stalling future vaccine research
The U.S. government has tens of millions of unused doses of messenger RNA (mRNA) COVID-19 vaccines, regularly trashing shots as they pass their expiration dates. It’s a dismal reflection on recent vaccine uptake, but it’s also a serious roadblock for scientists testing and developing vaccines that could protect against future variants of SARS-CoV-2—and the next pandemic. Developers need existing vaccines as a benchmark to compare with new candidates. But government contracts with the vaccinemakers, and the companies’ own policies, prohibit the use of the vaccines for research purposes.
“At this stage of the ...
Source: ScienceNOW - May 30, 2023 Category: Science Source Type: news
Why It Took So Long to Finally Get an RSV Vaccine
Respiratory syncytial virus (RSV) can dangerously compromise breathing, especially for infants and the elderly. But there has been no vaccine to prevent it—until today. On May 3, the U.S. Food and Drug Administration (FDA) approved the first vaccine against RSV, from GlaxoSmithKline (GSK), to prevent respiratory disease in people ages 60 and older. The Centers for Disease Control’s vaccine committee will make formal recommendations in June about who should receive the vaccine, but GSK says it currently has enough doses to vaccinate eligible people beginning this fall.
In studies involving 25,000 people that GSK...
Source: TIME: Health - May 3, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news
Changes in PD-1- and CTLA-4-bearing blood lymphocytes in ICU COVID-19 patients treated with Favipiravir/Kaletra or Dexamethasone/Remdesivir: a pilot study
This study evaluated the frequency of whole blood lymphocytes expressing PD-1 and CTLA-4 in COVID-19 patients upon admission to the intensive care unit (ICU) (i.e., severe) or infection ward (i.e., moderate) and after 7 days of antiviral therapy. COVID-19 patients were treated with either favipiravir or Kaletra (FK group, 11 severe and 11 moderate) or dexamethasone plus remdesivir (DR group, 7 severe and 10 moderate) for 7 days in a pilot study. Eight healthy control subjects were also enrolled. The frequency of PD-1+ and CTLA-4+ lymphocytes in whole blood was evaluated by flow cytometry. Patients on DR therapy had shorter...
Source: Iranian Journal of Allergy, Asthma and Immunology - April 1, 2023 Category: Allergy & Immunology Authors: Esmaeil Mortaz Hamidreza Jamaati Neda K Dezfuli Hakime Sheikhzade Seyed MohammadReza Hashemian Neda Dalil Roofchayee Frazaneh Dastan Payam Tabarsi Gert Folkerts Johan Garssen Sharon Mumby Ian M Adcock Source Type: research
